Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that new data on the phase 3 antifungal fosmanogepix, the antifungal isavuconazole (Cresemba^®) and the antibiotic ceftobiprole (Zevtera^®) will be presented at IDWeek 2026, which takes place from October 21 to 24 in Washington D.C., USA.

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “The breadth of data being presented at IDWeek across Basilea’s anti-infectives portfolio by us, our partners, collaborators and independent research groups, underscores the strong scientific interest in advancing the treatment of serious fungal and bacterial infections. These presentations continue to strengthen the evidence supporting our programs and their potential to address important unmet medical needs, including for pediatric patients.”

For further information please visit www.idweek.org. 

The fosmanogepix development program is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration of Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The agreement and federal funding are not an endorsement of study results, product, or company.

For Cresemba^® (isavuconazonium sulfate)¹ full U.S. prescribing information, please visit: https://www.astellas.us/docs/cresemba.pdf

For ZEVTERA^® (ceftobiprole medocaril sodium)² full U.S. prescribing information, please visit: https://www.zevtera.com/pi

Basilea’s ceftobiprole phase 3 program was funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. The contract and federal funding are not an endorsement of the study results, product, or company. Basilea was awarded approximately USD 111 million, or approximately 75 percent of the costs related to the Staphylococcus aureus bacteremia (SAB) and acute bacterial skin and skin structure infections (ABSSSI) phase 3 studies, regulatory activities and non-clinical work.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. 

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

This press release can be downloaded from www.basilea.com. 

References

1. Astellas Pharma Inc. is the organization responsible for commercializing Cresemba in the U.S.
2. Innoviva Specialty Therapeutics is the organization responsible for commercializing Zevtera in the U.S.

Attachment

• Press release (PDF)